TCR2 Therapeutics Inc. (TCRR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.2500 |
| Open | 3.2300 |
| Bid | 3.3000 x 1100 |
| Ask | 3.4000 x 800 |
| Day's Range | 3.2100 - 3.3700 |
| 52 Week Range | 2.0650 - 19.0300 |
| Volume | |
| Avg. Volume | 438,185 |
| Market Cap | 125.363M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4640 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.89 |
- GlobeNewswire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 46,600 shares of TCR2’s common stock to 2 new non-executive employees. The stock options were granted as an inducement material to the emp
- GlobeNewswire
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. “We are excited to announce Eric
- GlobeNewswire
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York. Alfonso Quintás-Cardama, Chief Medical Officer of TCR2 Therapeutics, will present an update on Company progress at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00PM E
